FDA Shames Anti-Generic Tactics, Putting Onus On Congress
The U.S. Food and Drug Administration on Thursday named and shamed drugmakers suspected of impeding lower-cost generics by withholding product samples, a splashy move that could jolt Congress into taking action....To view the full article, register now.
Already a subscriber? Click here to view full article